July 11th 2019
A look at recent developments in treatment and the cost implications of various autoimmune diseases.
January 1st 2019
Autoimmune diseases often impact many organ systems and are complex, requiring a number of specialists to manage them. Here’s a snapshot of an interesting new model that addresses care challenges of these diseases.
Most autoimmune diseases don’t have cures. Here are the top ways providers can manage and control them.
December 13th 2018
Here’s a look at three innovative drugs used to treat autoimmune conditions that made the news this year.
Because of the inflammatory nature of psoriasis, biologics are good drug candidates, but could affect cost and reimbursement.
Six Things Health Execs Should Know About Autoimmune Conditions
There has been an increase in the number of people with autoimmune diseases. Here’s what you should know about them.
Five Ways to Reduce Costs for Patients with Autoimmune Conditions
Autoimmune patients suffer a variety of comorbidities and often require extra care-here’s how the costs of that care can be reduced.
Six Facts About Autoimmune Conditions Health Execs Should Know
Top 6 Challenges in Managing Psoriasis
Managing psoriasis can be difficult for a variety of reasons. Here’s a look at the top six challenges that experts identified.
Six Ways Psoriasis Costs Extend Well Beyond Treatment of One Condition
Individuals with immune-mediated diseases, such as psoriasis, are at higher risk for having other immune-mediated diseases. Here’s how psoriasis can lead to other conditions, and the associated costs.
Top Specialty Pharmaceutical Pipeline Developments Health Execs Should Watch
Opinion: Time to Manage ‘Clinically Superfluous’ Drug Products to Control Costs
PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
How telemedicine will change care delivery and costs in 2018
Health systems realize that telehealth can help them achieve a wide range of objectives, from care coordination to readmission avoidance and market share expansion.
Will biosimilars deliver on expectations?
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
New challenges, opportunities in autoimmune disease treatment
Allegheny Health Network’s Susan Manzi, MD, MPH, discusses the healthcare needs of patients with lupus and other autoimmune disorders.
Autoimmune drug pipeline: What health execs should watch
New drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease-some recently approved and others coming down the pipeline-could have an impact on the industry.
Watch list 2017: Top therapeutic areas
Find out about the latest treatment and drug pipeline developments
Integrating pharmacy benefit, medical benefit cuts costs
Here’s how one non-profit health plan harnessed the power of medical and pharmacy data to rein in drug costs.
2 Clarke Drive Cranbury, NJ 08512